CSET’s Steph Batalis, Katherine Quinn, and Rebecca Gelles shared their expert analysis in an op-ed published by Barron's. Their piece examines the economic and scientific impact of proposed funding cuts to the National Institutes of Health (NIH), arguing that NIH-backed research plays a foundational role in driving medical innovation, biotechnology growth, and U.S. competitiveness.

CSET’s Steph Batalis shared her expert insight in an article published by TIME. The article examines how leading AI companies are increasingly restricting access to their most capable models, such as GPT-Rosalind and Claude Mythos, due to growing concerns around dual-use risks in areas like cybersecurity and biological research, and the broader question of who should govern access to these systems.

In an article published by Axios that discusses how AI-driven "biosurveillance" could be instrumental in detecting future pandemics or biological attacks, CSET's Steph Batalis provided her expert insights.

Recent government directives, international conferences, and media headlines reflect growing concern that artificial intelligence could exacerbate biological threats. When it comes to biorisk, AI tools are cited as enablers that lower information barriers, enhance novel biothreat design, or otherwise increase a malicious actor’s capabilities. In this explainer, CSET Biorisk Research Fellow Steph Batalis summarizes the state of the biorisk landscape with and without AI.

The recent Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence will have major implications for biotechnology. The EO demonstrates that the White House considers biorisk a major concern for AI safety and security. In this blog post CSET’s bio experts explain the bio-relevant takeaways of the executive order, add some additional context, and note their remaining questions about its implementation.